Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF - PubMed
4 hours ago
- #RSV prevention
- #public health impact
- #cost-effectiveness
- RSV is a major cause of medically attended lower respiratory tract disease (MA-LRTD) in infants in Japan.
- Japan is moving from high-risk targeted prophylaxis to broader RSV prevention with maternal immunization (MI) and nirsevimab.
- A study assessed public health and economic impacts of alternative MI and nirsevimab strategies within Japan's National Immunization Program (NIP).
- Strategies included NIP-aligned, mixed coverage (20/80, 50/50, 80/20 of nirsevimab/MI), and nirsevimab-only approaches.
- Increasing nirsevimab use reduced MA-LRTDs by 9.6% to 28.1%, with nirsevimab-only reducing MA-LRTDs by 34.3% and hospitalizations by 33.4%.
- Greater nirsevimab use improved outcomes, reduced costs, and had a lower number needed to immunize (NNI).
- Sensitivity analyses confirmed the robustness of these findings, favoring strategies with more nirsevimab use.